The role of proton pump inhibitor therapy in the management of eosinophilic esophagitis.
Expert Rev Clin Immunol
; 12(9): 945-52, 2016 Sep.
Article
em En
| MEDLINE
| ID: mdl-27097787
ABSTRACT
Eosinophilic esophagitis (EoE) is a chronic esophageal disease characterized by a Th2 inflammatory response triggered by food/environmental allergens. Solid data confirm that up to half of patients with suspected EoE achieve complete remission on proton pump inhibitors (PPI) therapy. This disease phenotype is currently labelled as PPI-responsive esophageal eosinophilia (PPI-REE). Albeit initially believed to represent gastro-esophageal reflux disease (GERD), evolving evidence has underscored that PPI-REE and EoE show a significant overlap regarding clinic, endoscopic, histologic, Th2 immune-mediated inflammation and gene expression features. Moreover, PPI therapy can effectively reverse Th2 inflammation and the EoE transcriptome expression in PPI-REE patients. Therefore, EoE and PPI-REE likely represent a common allergic disorder, where PPI therapy should be considered a short- and long-term therapeutic asset, along with diet and topical steroids.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Refluxo Gastroesofágico
/
Células Th2
/
Eosinofilia
/
Inibidores da Bomba de Prótons
/
Esofagite Eosinofílica
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Rev Clin Immunol
Ano de publicação:
2016
Tipo de documento:
Article